天津医药

天津医药 ›› 2016, Vol. 44 ›› Issue (10): 1259-1262.doi: 10.11958/20160547

• 临床研究 • 上一篇    下一篇

黄连成分与阿米卡星联合用药对多重耐药大肠埃希菌的体外活性研究

帅丽华 ， 姜登钊 ， 刘怀 ， 周小娟 ， 潘斌 ， 叶兴文   

  1. 1 江西九江， 九江学院附属医院检验科（邮编 332000）； 2 九江学院药学与生命科学学院省级重点实验中心； 3 九江学院附属医院重症医学科
  • 收稿日期:2016-06-13 修回日期:2016-07-29 出版日期:2016-10-15 发布日期:2016-10-21
  • 通讯作者: 姜登钊 E-mail:jiangdengzhao@126.com
  • 作者简介:帅丽华（1972）， 女， 学士， 副主任技师， 讲师， 主要从事细菌耐药性监测和抗感染治疗研究
  • 基金资助:
    江西省卫生厅 2014 年度科技计划项目（20143244）

In vitro activity of amikacin combined with the ingredient of coptis chinensis against multiple drug resistance of Escherichia coli#br# #br#

SHUAI Lihua,JIANG Dengzhao, LIU Huai, ZHOU Xiaojuan, PAN Bin, YE Xingwen   

  1. 1 Department of Clinical Laboratory, Jiujiang University Hospital, Jiangxi 332000, China; 2 Key Laboratory of Provincial Experiment Center, Institute of Medicine and Life Science of Jiujiang University; 3 Department of Intensive Care Unit, Jiujiang University Hospital
  • Received:2016-06-13 Revised:2016-07-29 Published:2016-10-15 Online:2016-10-21
  • Contact: JIANG Dengzhao E-mail:jiangdengzhao@126.com

PDF (PC)

3697

摘要： 目的 研究硫酸阿米卡星与黄连中成分黄连提取物、盐酸小檗碱、盐酸巴马汀联合用药对多重耐药大肠埃希菌的体外抑制作用。 方法 选择 2013—2014 年间对头孢噻肟耐药的 100 株大肠埃希菌， 筛选多重耐药大肠埃希菌， 并采用纸片扩散确证法进行超广谱 β-内酰胺酶（ESBLs）检测。 采用微量肉汤稀释法分别检测黄连提取物、盐酸小檗碱、盐酸巴马汀、硫酸阿米卡星对产 ESBLs 耐药大肠埃希菌的最小抑菌浓度（MIC）值， 再以 ATCC 25922 为质控菌株， 以棋盘式微量稀释法检测黄连提取物、盐酸小檗碱、盐酸巴马汀与硫酸阿米卡星联合用药对耐药大肠埃希菌的抑菌效果， 并计算联合用药的部分抑菌浓度（FIC）值。 结果 共筛选出 10 株产 ESBLs 耐药大肠埃希菌， 黄连提取物、盐酸小檗碱与硫酸阿米卡星联合用药后对 9 株耐药菌均表现为协同或相加作用， 而盐酸巴马汀与硫酸阿米卡星联合用药后对全部耐药菌均表现为协同或相加作用。 结论 盐酸巴马汀或盐酸小檗碱或黄连提取物与硫酸阿米卡星联合用于多重耐药大肠埃希菌感染， 具有较好的应用价值， 值得进一步研究。

关键词: 黄连属, 中草药, 小檗碱, 大肠杆菌, 微生物敏感性试验, 药物疗法, 联合, 阿米卡星, 盐酸巴马汀

Abstract: Objective To observe the antibacterial effects of amikacin sulfate combined with the ingredient of coptis chinensis： the extract of coptis chinensis, berberine hydrochloride and palmatine hydrochloride on multiple drug resistance (MDR) of Escherichia coli (E.coli) in vitro. Methods One hundred strains of E.coli checked out from 2013 to 2014 that showed resistence to cefotaxime were selected, and in which MDR to bacteria were determined. The extended-spectrum β- lactamases (ESBLs)-producing by Kirby-Bauer test. The minimum inhibitory concentrations (MIC) of the extract of coptis chinensis, berberine hydrochloride, palmatine hydrochloride and amikacin sulfate on ESBLs- producing E.coli were determined firstly, and then the sterilization effects of amikacin sulfate combined with the other three medicines were observed by broth microdilution checkerboard method together with their fractional inhibitory concentrations (FIC), with ATCC 25922 for quality control strains. Results Ten MDR E.coli were screened and proved to be ESBLs-producing. The inhibitory effects were enhanced in a synergistic or additive pattern when amikacin sulfate combined with the extract of coptis chinensis, berberine hydrochloride on nine of the ten MDR E.coli in vitro, where the inhibitory effects were a synergistic or additive pattern when amikacin sulfate combined with palmatine hydrochloride on all of the MDR E.coli in vitro. Conclusion Palmatine hydrochloride or berberine hydrochloride or the extract of coptis chinensis combined with the amikacin sulfate has significant value in treatment of MDR E.coli, which is worthy of further study.

Key words: coptis, drugs, Chinese herbal, berberine, Escherichia coli, microbial sensitivity tests, drug therapy, combination, amikacin, palmatine hydrochloride